Question 1

What are the potential risks and side effects of the anti-CD19 CAR-NK cells?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL clinical trial (NCT04887012). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to other options I have?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL clinical trial (NCT04887012). Contact the study team or your healthcare provider for specific answers.

Question 3

What is the expected duration of my participation in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL clinical trial (NCT04887012). Contact the study team or your healthcare provider for specific answers.

Question 4

Will I need to undergo any specific tests or procedures during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL clinical trial (NCT04887012). Contact the study team or your healthcare provider for specific answers.

Question 5

How will my health be monitored throughout the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL clinical trial (NCT04887012). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects or my condition worsens?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL clinical trial (NCT04887012). Contact the study team or your healthcare provider for specific answers.

What this study is about